Sodium Channel Blockers
Chemical wrenches thrown into the fast lane. How we alter conduction velocity and why the heart rate dictates the drug's power.
Antiarrhythmic drugs are not magic bullets. They are simply chemical wrenches thrown into specific ion channels to alter the three fundamental properties of cardiac tissue: automaticity, conduction velocity, and refractoriness.
When a patient develops a fast, dangerous rhythm, our instinct is to reach for a pill to suppress it. But to understand how these drugs work—and how they can inadvertently kill the patient—we must return to the biophysics of the cell membrane.
We start with the fast lane: the sodium channel.
The Target (Phase 0)
In Volume I, we learned that the explosive upstroke of the working myocyte's action potential (Phase 0) is driven by millions of fast sodium channels snapping open simultaneously. This sudden rush of positive charge flips the intracellular voltage from -90 mV to +20 mV in a fraction of a millisecond.
The speed of this voltage change is known as Vmax. A steep, aggressive Vmax generates a powerful electrical current that easily kicks the neighboring cell past its own threshold.
Class I antiarrhythmic drugs block these sodium channels. By physically plugging the pore, they reduce the total number of channels available to open. With fewer channels participating, the inward rush of sodium is blunted. The upstroke loses its steepness. Vmax decreases.
The Consequence
When you blunt the upstroke of the single cell, you change the behavior of the entire tissue.
Because the cell depolarizes more slowly, it takes longer to generate enough voltage to trigger its neighbor. The wavefront moves more sluggishly from cell to cell. Conduction velocity falls.
On the surface ECG, the time it takes for the electrical wave to sweep across the ventricular mass is represented by the QRS complex. When conduction velocity slows down, the QRS physically stretches out. The wider the QRS becomes, the heavier the sodium blockade.
Use-Dependence
This brings us to the most brilliant concept in Class I pharmacology: use-dependence.
These drugs do not bind well to closed, resting channels. They are structurally engineered to slip into the channel pore only when the channel is open or inactivated—in other words, only when the cell is firing. During diastole, when the channel resets to its resting state, the drug falls off.
Therefore, the faster the heart beats, the more times the channels open, the more opportunities the drug has to bind, and the stronger the block becomes. The drug is strongest exactly when you need it most (during a tachycardia), and it relaxes its grip during normal sinus rhythm.
The Subclasses
All Class I drugs block sodium channels, but they are not created equal. We divide them into three subclasses—1B, 1C, and 1A—based entirely on their unbind rate. How quickly does the wrench fall out of the gears?
Class 1B: The Fast Release
Lidocaine is the classic 1B agent. It has a very fast unbind rate. If the heart is beating at a normal 70 bpm, the diastole between beats is long enough for every single lidocaine molecule to detach from the sodium channels. There is zero accumulation, zero conduction slowing, and no QRS widening on the baseline ECG.
Lidocaine only works when the heart rate is screaming fast (like Ventricular Tachycardia), giving the drug no time to unbind between beats. It also works preferentially in ischemic tissue, where sick cells spend a prolonged amount of time in the depolarized (inactivated) state, holding the drug tight.
Class 1C: The Death Grip
Flecainide is a 1C agent. It has a very slow unbind rate. Once it binds to an open channel, it stays stuck.
Even at a resting heart rate of 60 bpm, flecainide does not fully detach before the next beat arrives. The blockade accumulates. This is why patients on flecainide exhibit baseline QRS widening on their resting ECG. The drug imposes a heavy, continuous drag on conduction velocity.
Class 1A: The Messy Middle
Drugs like procainamide and quinidine sit in the middle. Their unbind rate is intermediate. However, they come with a messy side effect: they also block potassium channels. While they slow Phase 0 (widening the QRS), they also prolong Phase 3 repolarization (prolonging the QT interval).
Because Class 1C drugs impose such a heavy drag on conduction, they can alter the behavior of an arrhythmia in terrifying ways.
Imagine a patient in Atrial Fibrillation. The atria are firing chaotically at 400 bpm. You give flecainide. The drug slows conduction velocity so much that the chaotic wavelets fuse into a single, slower, highly organized circuit. The AFib organizes into Atrial Flutter at 250 bpm.
Normally, the AV node protects the ventricles from 400 bpm AFib by blocking most of the impulses. But at a slower, organized 250 bpm, the AV node might suddenly conduct every single beat (1:1 conduction).
The ventricular rate instantly jumps to 250 bpm. Because the flecainide is widening the QRS at the same time, the rhythm looks like a wide, terrifying Ventricular Tachycardia, and the patient's blood pressure collapses. This is why you must never prescribe flecainide without an AV nodal blocking agent (like a beta-blocker) on board to guard the gate.
Key Takeaways
- The Target: Class I drugs block fast sodium channels, blunting the upstroke (Phase 0) and decreasing Vmax.
- The Effect: Decreased Vmax slows conduction velocity across the tissue, stretching the QRS complex on the ECG.
- Use-Dependence: These drugs bind specifically to open or inactivated channels, meaning their blocking power multiplies as the heart rate increases.
- The Subclasses: 1B (lidocaine) unbinds quickly and only works at fast rates. 1C (flecainide) unbinds slowly and widens the QRS even at rest.
- The Danger: Flecainide can organize fast AFib into a slower Atrial Flutter, which can conduct 1:1 down the AV node, causing a dangerous wide-complex tachycardia.